 |
|
|
| |
An Integrated Safety Analysis of Daclatasvir + Sofosbuvir,
With or Without Ribavirin, in Patients With Chronic HCV Infection
|
| |
| |
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
Landis C,1 Nelson DR,2 Sulkowski M,3 Ruane P,4 Mills A,5 Poordad F,6 Wyles D,7 Bhore R,8 Ackerman P,9 Rana K,9 Swenson ES,9 Noviello S8
1University of Washington School of Medicine, Seattle, WA; 2University Of Florida, Dept. of Hepatology, Gainesville, FL; 3Johns Hopkins University, Baltimore, MD; 4Ruane Medical and Liver Health Institute, Los Angeles, CA; 5Anthony Mills MD, Inc; 6Texas Liver Institute, University of Texas Health Sciences, San Antonio, TX; 7University of California, San Diego, CA; 8Bristol-Myers Squibb, Princeton NJ; 9Bristol-Myers Squibb Research and Development, Wallingford, CT.
|
| |
|
|
|
|
|
